Summary
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
History
Masimo was founded in 1989 to develop noninvasive blood-oxygen monitoring technology. In 1995, Masimo developed its first commercial product, the Rainbow Pulse Oximeter, which represented a revolutionary advancement in noninvasive patient monitoring technology. Over time, Masimo has grown to become one of the largest medical technology companies in the world, developing products used in more than 100 countries.
Mission
Massimo Dutti is committed to offering all its customers a highstandard of excellence, quality, health and safety in its products,and communicating this in a clear and transparent manner.
Vision
Its products are made ethically and responsibly.
Key Team
Mr. Tao Leopold Levy (Exec. VP of Bus. Devel.)
Mr. Yongsam Lee (Exec. VP & Chief Information Officer)
Mr. Thomas Samuel McClenahan (Exec. VP, Gen. Counsel & Corp. Sec.)
Dr. Steven J. Barker (Chairman of Scientific Advisory Board & Chief Science Officer)
Mr. Eli Kammerman (VP of Bus. Devel. & Investor Relations)
Mr. Jon Coleman (Pres of Worldwide Sales, Professional Services & Medical Affairs)
Mr. Anand Sampath (Exec. VP of Operations & Clinical Research)
Recognition and Awards
Masimo has received numerous awards for its pioneering technologies, including: “Best in KLAS” awards for neonatal and adult pulse oximetry; Innovation awards from Frost & Sullivan, the American Association for Respiratory Care, the American Society of Anesthesiologists, and CTA; and multiple Juelich Research Awards in recognition of Masimo’s research and development achievements.
References
United States 
